Notably, IGF-1 gene therapy ameliorated peripheral nerve injury at both presymptomatic and symptomatic stages of SAPP, these findings are relevant to both chronic-progressive and relapsing-remitting forms of CIDP. This evidence concerns the gene IGF1 and chronic inflammatory demyelinating polyradiculoneuropathy.